Research Paper Volume 16, Issue 5 pp 4841—4861
HOXC9 characterizes a suppressive tumor immune microenvironment and integration with multiple immune biomarkers predicts response to PD-1 blockade plus chemotherapy in lung adenocarcinoma
Figure 1. Analyses of HOXC9 expression and the diagnostic and prognostic value in LUAD. (A) The expression distribution of HOXC9 in tumor tissues and normal tissues with TIMER2, respectively; (B–E) The correlation between HOXC9 expression and clinical variables of LUAD; (F) The HOXC9 protein level in adjacent healthy tissue; (G) and in the tumor tissue; (H) The diagnostic value of HOXC9 in LUAD; (I) The OS analysis of HOXC9 in LUAD patients. (*, P<0.05; **, P<0.01; ***, P<0.001).